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Abstract 
The overall purpose of this project is to successfully synthesize multiple analogs of L-
serine that can act as competitive inhibitors of phosphatidylserine synthase from the fungal 
species Candida albicans and ultimately serve to provide vital information regarding the  
potential development of anti-fungal therapeutics against the fungal infection Fungal 
Endocarditis. The focus of this project centers around the necessity to determine a process by 
which researchers can synthesize a pharmaceutical drug that can put an end to the harmful 
impact of fungal infections within immunocompromised individuals. Biofilm formation on 
prosthetic heart valves leads to Fungal Endocarditis, which more often than not results in death 
for the infected individuals. The hope, by focusing on the differences in biochemical pathways 
between C. albicans and affected humans, is to discover a drug that can effectively render the 
functioning of C. albicans cells useless. While C. albicans requires the use of phosphatidylserine 
synthase to create phosphatidylserine, the biochemical pathway within humans follows an 
entirely different route. This difference in biochemical pathways between C. albicans and 
humans is a focal point of this research and provides a possible road for intervention of the 
adverse effects of C. albicans against humans. By competitively inhibiting phosphatidylserine 
synthase, the virulence of C. albicans is eradicated while mammals are not negatively affected. 
The compounds being synthesized for competitive inhibition testing are (S)-3-bromo-N-(1-
carboxy-2-hydroxyethyl)propan-1-aminium, (S)-3-azido-N-(1-carboxy-2-hydroxyethyl)propan-
1-aminium, and (S)-N-(1-carboxy-2-hydroxyethyl)prop-2-yn-1-aminium. 
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Compounds Utilized and Synthesized 
L-serine 
 
tert-butyl O-(tert-butyl)-L-serinate 
hydrochloride (1) 
 
tert-butyl O-(tert-butyl)-L-
serinate (2) 
 
1,3-dibromopropane (3) 
 
1-azido-3-bromopropane (4) 
 
3-bromo-1-propyne (5) 
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(S)-3-bromo-N-(1-carboxy-2-
hydroxyethyl)propan-1-aminium (6) 
 
(S)-3-azido-N-(1-carboxy-2-
hydroxyethyl)propan-1-aminium (7) 
 
(S)-N-(1-carboxy-2-
hydroxyethyl)prop-2-yn-1-aminium 
(8) 
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Introduction and Background 
Fungal Endocarditis is one of the most prominent fungal infections still prevalent today 
that, regardless of the treatment methods used, has led to a high mortality rate, especially towards 
individuals who possess weaker immune systems (Mishra et al., 2007). Searches for a new type 
of drug to slow down the effects of Fungal Endocarditis is a necessity.  
Fungal Endocarditis tends to appear in higher frequency in individuals who have 
cardiovascular systems that have undergone numerous surgical operations or in individuals who 
were born with abnormal hearts. Normally, one’s innate defense systems prove sturdy enough to 
hold off the invasion of the fungal species into the heart altogether. In individuals with impaired 
defense systems, however, the fungal species manages to invade the heart through transportation 
within the blood stream.9 The human heart can pump blood at an incredibly fast rate; some 
fungal invasions are thwarted immediately if the fungal species is not able to establish its 
presence fast enough before the incoming blood supply is pumped out of the aorta towards the 
rest of the body. If the fungal species is able to establish its presence within the innermost layer 
of tissue within the heart, the endocardium, the fungal species can then grow within the heart and 
lead to complications for the affected individual.  
The complications that can plague an affected individual are numerous. Although the 
effects can range dramatically, the individuals affected tend to remain fairly constant: as one’s 
heart strength and condition declines, one becomes more susceptible to the fungal infection 
Fungal Endocarditis. Congestive heart failure and possessing a prosthetic heart valve, for 
example, tend to increase one’s chance of infection. Regardless of the reason why an individual 
may become infected, the outcome of infection is dismal. In a case study of 70 infected 
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individuals between 2000 and 2010, the average survival rate after 1 year of infection was only 
41%.1 
The fungal species that has been determined to be the initiator of the majority of Fungal 
Endocarditis cases is C. albicans.8 The majority of these infections are caused by the biofilm 
formation of C. albicans on implanted cardiac devices such as prosthetic heart valves, indwelling 
catheters, and pacemakers.5 The effects of C. albicans are not solely limited to the cardiovascular 
system; C. albicans has been shown to play a role in multiple oral cavity diseases, including 
chronic periodontitis, dental caries, and angular cheilitis.7  
Biofilm formation is prefaced by an organism’s attachment to a surface and production of 
extracellular polysaccharides.4 Once the organism is able to establish its presence and then 
replicate, the biofilm growth gradually increases in a rate corresponding to the collective rate  of 
replication of all organisms within the biofilm. For the Candida species, biofilm formation 
involves the “matrix-enclosed microcolonies of yeasts and hyphae, arranged in a bilayer 
structure.”5 After a biofilm has formed and spread to a significant size, it begins behaving as a 
colony of organisms that group together. Individual organisms within a biofilm can communicate 
with one another and fight off complete eradication more easily than an isolated individual 
organism is able to do alone. If a synthesized drug were able to eradicate the wild type species of 
C. albicans, the individual fungal organisms would likely die prior to replication. In a biofilm, 
however, the odds of one of the organisms possessing a beneficial mutation are likely. It is very 
possible that a synthesized drug would be ineffective against a biofilm because if one of the 
organisms can manage to survive and replicate, resistance is conferred to the biofilm. Thus, 
survival and replication is more likely for a biofilm than for isolated organisms.  
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The first step in attempting to prohibit the negative effects of a biofilm created by C. 
albicans is to stop or slow down the formation of the biofilm altogether. The goal of this project 
is to synthesize a compound that can serve as a competitive inhibitor in a key biochemical 
reaction present within C. albicans but not within mammals. Specifically, the goal of this 
research is to find a suitable way to inhibit the production of phosphatidylserine within C. 
albicans without affecting biochemical reactions within mammals along the way.  
Competitive inhibitors have the ability to reduce the binding of substrates to its desired 
enzyme, effectively limiting the enzyme activity. Competitive inhibitors bind to the same 
enzyme that substrates naturally bind to, thus creating a competition between the inhibitors and 
the substrate. To synthesize a suitable competitive inhibitor, the inhibitor needs to mimic the 
binding characteristics of the substrate’s binding site. In effect, the inhibitor needs to serve the 
purpose of being a “clone” of the substrate, effectively reducing the amount of binding the 
substrate can have with respect to the desired enzyme. 
The targeted enzyme of choice present within C. albicans is the specific 
phosphatidylserine synthase, Cho1. Cho1 is a great target enzyme for a competitive inhibitor for 
two main reasons: 1. The synthesis of phospholipids in C. albicans, which involves the use of 
phosphatidylserine synthase, follows a different pathway than the phospholipid synthesis within 
mammals, which does not require phosphatidylserine synthase for phospholipid synthesis.2 2. 
The substrate that attaches to phosphatidylserine synthase is serine, which is a relatively simple 
molecule to slightly alter while keeping its core backbone intact.   
The effect of inhibition of phosphatidylserine synthase studied in mouse models has 
shown a decrease in the amount of phosphatidylserine produced. As the production of 
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phosphatidylserine declines, the amount of masking of cell wall beta (1-3)-glucan is 
subsequently decreased as well.3 As a result, host immunity stands a better chance to locate the 
invading fungal species and fight off the Fungal Endocarditis infection.  
In general, a human’s immune system is broken down into innate and adaptive divisions; 
the innate division is always active against infection while the adaptive immune system targets 
specific pathogens. Once an innate division cell spots an invader, it can signal to the adaptive 
immune system to help ward off the invading species. But what happens when the invader isn’t 
spotted? This is why Fungal Endocarditis has grown to be such a major problem. 
Phosphatidylserine can help mask the beta(1,3)-glucan cell wall from the innate immune system. 
But once the masking of the cell wall is diminished, the fungal species can be spotted by the 
innate immune system and ultimately attacked and destroyed by the adaptive immune system. 
Causing a decrease in the production of phosphatidylserine, by competitive inhibition of 
phosphatidylserine synthase, can in turn lead to the spotting and destruction of invading fungal 
species that would otherwise lead to the fungal infection Fungal Endocarditis.  
The desired final products within this research group will be analogs of L-serine that have 
the potential to bind to phosphatidylserine synthase and hopefully limit the growth and 
proliferation of C. albicans as a subsequent result. 
The structure of serine contains four main substituents that extend from a central carbon 
atom. Three of the four substituents are consistent with all naturally occurring amino acids: a 
hydrogen atom, a carboxyl group, and an amino group. The fourth substituent, which 
distinguishes serine from other amino acids, is an R group that is represented by CH2OH. Of the 
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twenty naturally occurring amino acids, serine is one of only five of the amino acids that are 
polar, with the other polar amino acids including asparagine, cysteine, glutamine, and threonine.  
In a typical amino acid chain, a peptide bond is formed when the nitrogen atom contained 
within the amino substituent group on one amino acid attacks the carbon atom contained within 
the carboxyl substituent group of another amino acid, resulting in a loss of a water molecule. 
Within the research performed in this project, we want to emulate a similar attack by the amino 
substituent group, but in this instance, we wish to manipulate the nucleophilic nitrogen of the 
serine amino background into initiating a substitution reaction with 1,3 – dibromopropane (3), 1-
azido-3-bromopropane (4), and 3-bromo-1-propyne (5) respectively in the hopes of obtaining 
serine analogs that are very similar, but still possess differences, with natural serine.  
The starting material for our compound syntheses is tert-butyl O-(tert-butyl)-L-serinate 
hydrochloride (1) instead of natural serine. By utilizing Compound 1 instead of serine, we can 
manipulate the nucleophilic nitrogen of Compound 1 into initiating substitution reactions with 
1,3 – dibromopropane (3), 1-azido-3-bromopropane (4), and 3-bromo-1-propyne (5) instead of 
intramolecularly interacting with the hydroxyl groups that would have been present within 
natural serine. Because the starting material has O-(tert-butyl) groups instead of OH groups, the 
nucleophilic nitrogen is unable to intramolecularly interact with the OH groups of natural serine. 
As a result, it is now possible to effectively vary the backbone of serine. After the substitution 
reaction is completed, a deprotection step removes the tert-butyl groups and the final synthesized 
compounds resemble natural serine, although their amino group backbones have been slightly 
altered.  
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To date, the serine analogs that have undergone substitution with 1-azido-3-
bromopropane (4) and 3-bromo-1-propyne (5) have been tracked intracellularly by utilizing 
clickable tags. Through the use of the two clickable substrate analogs in a phosphatidylserine 
synthase assay performed by graduate student Chelsi Cassilly, it has been discovered that both 
analogs, Compound 7 and Compound 8, compete with serine and effectively inhibit the 
production of phosphatidylserine. The third serine analog synthesized within this research group, 
Compound 6, which involves the substitution of 1,3-dibromopropane (3), is hoped to be even 
more effective in causing competitive inhibition of Cho1.   
While the relative inhibition effects of Compounds 7 and 8 are merely designed to 
discover more information about the binding site characteristics of Cho1, Compound 6 has the 
potential to make strong headway in the future design of a pharmaceutical drug to fight off a C. 
albicans infection. Compound 6’s backbone possesses a bromine leaving group that is very 
prone to substitution reactions. If the binding site of Cho1 potentially were to initiate a 
substitution reaction with Compound 6, the enzyme’s binding site would be drastically altered. 
In essence, Compound 6 could potentially serve as an irreversible competitive inhibitor of Cho1 
if the enzyme’s binding site was rendered unable to bind serine after interacting with Compound 
6.  
Figure 1 – Preliminary Inhibition Results for Compound 7 
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 Based on the results from Figure 1, the phosphatidylserine synthase Chol within C. 
albicans in increasingly inhibited as the concentration of Compound 7 increases. When 
Compound 7 is not present, the formation of phosphatidylserine, as monitored by a scintillation 
counter, is approximately 16 nmol/mg protein. When only 0.5 mmol of Compound 7 is 
introduced, however, the production of phosphatidylserine decreases by over 50%. When 5 
mmol of Compound 7 or more are introduced, the production of phosphatidylserine is 
completely diminished and it becomes increasingly suggestive that Compound 7 is a suitable 
competitive inhibitor of Cho1.  
Figure 2 – Preliminary Inhibition Results for Compound 8 
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 Based on the results from Figure 2, the phosphatidylserine synthase Cho1 within C. 
albicans is increasingly inhibited as the concentration of Compound 8 increases. When only 0.5 
mmol of Compound 8 introduced, the reduction in production of phosphatidylserine is minimal. 
When 5 mmol of Compound 8 are introduced, however, the production of phosphatidylserine 
decreases by roughly 50%. With 25 mmol of Compound 8, the production of phosphatidylserine 
is entirely diminished, again suggesting the successful inhibition of Cho1 by a synthesized 
compound made within this research group.  It should be noted that standard error bar analysis of 
Figures 1 and 2 would suggest that the results obtained from Compound 8 are more reliable than 
the results obtained for Compound 7 at this time.  
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Synthesis Design 
Figure 3 – Synthesis Scheme 
  
The above synthesis sequence portrayed by Figure 3 proceeds by means of three general 
reactions: respectively, extraction of HCl by use of NH3, an Sn2 substitution reaction, and 
deprotection.  
In the initial portion of Figure 3, the starting material 1 is a salt. The NH2 portion of the 
starting material is a free base and will be protonated easily in the presence of acid. Because HCl, 
a strong acid, is present, the NH2 portion of the starting material has been protonated to 
+NH3 
and is a hydrochloric salt. In an attempt to form the basic NH2 again, extraction with NH3 helps 
remove HCl from the solution. 
In the second portion of Figure 3, an SN2 substitution reaction occurs that involves the 
nucleophilic attack of the nitrogen atom within NH2 and the departure of the bromine leaving 
group on Compounds 3, 4, and 5. The mechanism of the SN2 substitution reaction can be seen in 
Figure 4 on the following page.  
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Figure 4 – SN2 Substitution Reaction 
 
 In the final portion of Figure 3, deprotection of the tert-butyl groups occurs with use of 
trifluoroacetic acid (TFA)1.  The deprotection step involves the removal of both tert-butyl groups 
and replacement of hydrogen atoms in their place.  
Figure 5 – Deprotection Step 
 
 
 
 
 
                                                        
1 Hydrochloric acid (HCl) in methanol (MeOH) was later utilized as a deprotecting group instead 
of TFA. 
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Experimental Procedure 
In the overall reaction, the addition of Compounds 3, 4, and 5, respectively 1,3 – 
dibromopropane, 1-azido-3-bromopropane, and 3-bromo-1-propyne, differentiated the various 
portions of the synthesis reactions. Regardless of which of the three compounds was utilized for 
each respective portion of the experiment, each of the general schemes followed the same 
general outline. The outline of the synthesis involved 5 distinct parts.  
Part 1: The Extraction of tert-butyl O-(tert-butyl)-L-serinate hydrochloride (1) into  tert-
butyl O-(tert-butyl)-L-serinate (2) 
First, Compound 1 (0.100 g) was weighed and subsequently transferred into a separatory 
funnel for extraction using ammonia (5%, 20 – 25 mL) and dichloromethane (80 mL). The 
funnel was stoppered and shaken 3 separate times, with the gaseous byproduct being allowed to 
exit the funnel after each individual shake by slightly opening the separatory funnel’s valve with 
the valve oriented in an upward fashion. The bottom, organic layer of solution (the one 
containing the DCM) was collected into a clean 250-mL Erlenmeyer flask. The DCM was added 
3 to 5 separate times until the resulting solution within the Erlenmeyer flask was approximately 
100 mL. During each individual section of the extraction, the bottom (organic) layer was allowed 
to separate from the top (aqueous) layer prior to draining the organic layer through the bottom of 
the separatory funnel. In an effort to diminish the amount of aqueous contamination within the 
organic layer, the organic layer was filtered through the bottom of the separatory funnel instead 
of being poured out of the top of the separatory funnel (where the aqueous layer was residing).        
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Next, to remove the residual H2O, a drying agent, anhydrous sodium sulfate, was utilized. 
The collected organic layer was then decanted into a clean, pre-weighed 250 mL round bottom 
flask, leaving the drying agent behind in the Erlenmeyer flask.  
By utilizing a rotary evaporator, the solvent layer containing DCM within the round 
bottom flask was removed by rotating the rotary evaporator at a temperature of 55C. After the 
rotary evaporator had removed nearly all, if not all, of the DCM layer, the round bottom flask 
was next placed on high vacuum overnight. The resulting product was Compound 2.  
Part 2: The Preparation of Compounds 3, 4, and 5 
For the first portion of the experiment, 1,3 - dibromopropane (3) was already a reactant 
possessed within Dr. Best’s laboratory. No further steps were required to prepare the desired 
haloalkane. 
For the second portion of the experiment, 1-azido-3-bromopropane (4) was synthesized 
by reacting sodium azide (0.235 g, 3.6 mmol, 1.18 eq ) with 1,3-dibromopropane (310 L, 3.05 
mmol, 1 eq) in a 250 mL round bottom flask that already contained acetonitrile (20-25 mL). A 
stir bar was added and the flask was then placed within an oil bath and refluxed overnight at 
50C with stirring. After refluxing and stirring overnight, the round bottom flask was removed 
from the oil. By utilizing deionized water (20 mL) and DCM (approximately 75 mL in total), an 
extraction was performed that collected the bottom organic layer in a clean Erlenmeyer flask. 
Sodium sulfate was used to remove any residual H2O in the remaining solution within the 
Erlenmeyer flask. The solution was then transferred to a round bottom flask that was 
subsequently placed on the rotary evaporator to remove the DCM solvent in the solution. 1 H – 
Nuclear Magnetic Resonance (1H-NMR) and mass spectrometry were utilized to determine if 
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Compound 4 had formed. The final product of this step was transferred, using copious amounts 
of DCM, into a clean vial and stoppered. The results of Compound 4’s synthesis are portrayed in 
Figures 6 and 7 within the Results and Discussion section of this report.  
For the third portion of the experiment, 3-bromo-1-propyne (5) was a compound already 
possessed within Dr. Best’s laboratory.  
Part 3: The Addition of Compounds 3, 4, and 5 to Compound 2 
During this lengthier phase of the experiment, multiple steps were performed that 
attempted to first specifically add Compounds 3, 4, or 5 onto the nitrogen atom within 
Compound 2 then deprotect and subsequently remove the tert-butyl groups located on 
Compound 2 to reach the desired serine analog.  
First, dry DMF (20 mL) was added to the round bottom flask containing Compound 2 
(0.098 g, 0.451 mmol, 1 eq) retrieved from extraction in Part 1 of the experiment. Next, 
potassium carbonate (0.160 g, 1.16 mmol, 2.57 eq) was added to the flask and the solution was 
stirred for 20 minutes. Then, Compound 3 (60 L, 0.59 mmol, 1.3 eq) was added to the solution 
within the round bottom flask using a pipet. The round bottom flask was then placed in an oil 
bath at 55 C and refluxed while stirring overnight.  
The previous step described the procedure followed for the substitution reaction 
involving Compound 3 in the hope of creating Compound 6. Similar workups were performed 
for Compounds 4 and 5 in the hopes of respectively creating Compounds 7 and 8 as well.   
For the reaction to produce Compound 7, Compound 2 (0.094 g, 0.433 mmol, 1 eq), 
potassium carbonate (0.150 g, 1.085 mmol, 2.5 eq), Compound 4 (0.085 g, 0.52 mmol, 1.2 eq), 
and dry DMF (20 mL) were utilized.  
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For the reaction to produce Compound 8, Compound 2 (0.200 g, 0.920 mmol, 1 eq), 
potassium carbonate (0.318 g, 2.30 mmol, 2.5 eq), Compound 5 (0.1053 mL, 1.18 mmol, 1.28 
eq), and dry DMF (20 mL) were utilized. The synthesis of Compound 8 was performed by 
graduate student Shahrina Alam.   
The reflux reaction was stopped after 24 hours. The next addition to the round bottom 
flask included copious amounts of ice with cold deionized water. The solution within the round 
bottom flask was placed into a separatory funnel and extracted using DCM (75 mL). The bottom, 
organic layer was collected in an Erlenmeyer flask and was dried over sodium sulfate. The 
solution was decanted into a clean 250 mL round bottom flask and placed on the rotary 
evaporator at approximately 85 C.  
Next, the resulting solution was purified by utilizing column chromatography with an 
eluent of 25% ethyl acetate in hexane. Fractioning columns were utilized to help isolate specific 
solutions during the course of the synthesis reaction. The fractions collected were placed within 
test tubes and allowed to sit undisturbed for at least 12 hours to allow for the product to become 
better concentrated.  
The test tubes were then separately spotted onto TLC plates. The TLC plates were in turn 
run through a TLC chamber containing 35% ethyl acetate – 65% hexane, observed under UV 
light, and then reacted with ninhydrin, potassium permanganate, and potassium permanganate 
respectively for the intermediates formed by addition of Compounds 3, 4, and 5. The prominent 
spots that were portrayed by the TLC plates represented the fractions that potentially contained 
the desired product. The corresponding test tubes for the positive fractions were collected, rinsed 
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with DCM, and transferred into a round bottom flask that was placed on the rotary evaporator at 
55 Celsius.  
Next, trifluoroacetic acid (TFA) in a solvent of DCM was utilized to deprotect the tert-
butyl groups located on the ends of Compound 2. In latter stages of the experiment, HCl  was 
substituted in the place of TFA as a deprotecting agent with methanol used as a solvent instead 
of DCM. Prior to the addition of TFA, DCM (15 mL) was added to the round bottom flask 
containing the desired intermediate. Then, TFA (8 mL) was added to the round bottom flask 
drop-wise and the solution was stirred overnight. After 24 hours, DCM was placed in the round 
bottom flask to assist the evaporation of TFA by the rotary evaporator. The solution was placed 
on the rotary evaporator 3 separate times after placing DCM into the round bottom flask before 
each respective solvent evaporation. After all of the TFA had evaporated, the solution was placed 
on high vacuum to ensure that all surrounding solvent had been successfully removed prior to 
proceeding with the next phase of Part 3. 
To further purify the intermediate, reverse phase column chromatography was performed. 
The preconditioning of the reverse phase column included the following steps: 10 mL of 100% 
methanol; 8 mL of methanol and 2 mL of water; 6 mL of methanol and 4 mL of water; 4 mL of 
methanol and 6 mL of water; 2 mL of methanol and 8 mL of water; 10 mL of water. After each 
separate precondition was run through the column, the intermediate was then added to the 
reverse phase column using a pipet to transfer the solution. Each of the following “additions” 
were placed within the round bottom flask containing the intermediate and pipetted into the 
column from the flask, dragging along the intermediate gradually with them: 10 mL of 100% 
water; 8 mL of water and 2 mL of methanol; 6 mL of water and 4 mL of methanol; 4 mL of 
water and 6 mL of methanol; 2 mL of water and 8 mL of methanol; 10 mL of methanol.  
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The reverse phase column yielded a range of 10 - 12 test tubes. TLC analysis was then 
performed to determine the fractions that likely possessed the desired final compound. The 
fractions corresponding to the prominent spots observed after staining with ninhydrin during 
TLC analysis were then rinsed thoroughly with methanol, transferred to a round bottom flask, 
and again placed on the rotary evaporator. After rotary evaporation, the final compounds present 
within the round bottom flask were either Compound 6, 7, or 8. To confirm the presence of the 
final products, NMR and mass spectrometry analysis were utilized.  
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Results and Discussion 
 There were a total of four different compounds produced – one intermediate (4) and three 
final products (6, 7, and 8). Both 1H-NMR and 13C-NMR were taken on a 500 MHz NMR 
spectrometer and mass spectrometry results were obtained by use of DART-TOF. For the 
intermediate formed in Part 2 of the Experimental Procedure, 1 – azido – 3 – bromopropane (4), 
1H-NMR and mass spectrometry were performed to analyze the potential formation of the 
desired intermediate. The results from 1H-NMR and mass spectrometry for Compound 4 can be 
viewed in Figures 6 and 7 respectively. 
Figure 6 – 1H-NMR Results for Compound 4 
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 There are a total of 6 hydrogen atoms present within 1-azido-3-bromopropane (4) and 
one should expect 1H-NMR data to portray integrated peaks equal to approximately 6. One 
should also expect that the peak representing the hydrogen atoms located nearest the bromine 
atom should be shifted further downfield than the peak representing the hydrogen atoms located 
on the carbon atom nearest the N3 group. These expectations are due to bromine’s high 
electronegativity leading to a shift further downfield for hydrogen atoms near the bromine 
molecule. 
The 1H-NMR data collected match the expected results. There were separate peaks at 
3.54 ppm and 2.30 ppm, represented by letters a and c, that corresponded to the hydrogen atoms 
nearest the bromine atom and azide group respectively. In addition, the total integrated values of 
the peaks within the spectrum summed to 6.21, suggesting the presence of 6 hydrogen atoms 
within Compound 4 as anticipated. 
Figure 7 – Mass Spectrometry for Compound 4 
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 The exact mass of the molecular ion of Compound 4 is 163.982 m/z. The observed 
molecular ion from mass spectrometry was 163.97042 m/z as portrayed in Figure 7, containing a 
percent error of only 0.0000706 % (70.6 ppm).  
 To determine if the formation of (S)-3-bromo-N-(1-carboxy-2-hydroxyethyl)propan-1-
aminium (6) occurred properly, 1H-NMR, 13C-NMR, and mass spectrometry were analyzed. The 
results are shown in Figures 8, 9, and 10 respectively.  
Figure 8 – 1H NMR for Compound 6 
 
 The hydrogen atoms present on the hydroxyl –OH, carboxylic acid –COOH, and the 
amine –NH2 were shifted much further downfield than the area of interest within the 1H-NMR 
spectra and will not be discussed during analysis. For the remaining 9 hydrogen atoms, it was 
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expected for the 1H-NMR spectrum to portray 5 distinct peaks corresponding to the 5 distinct 
hydrogen atoms (or equivalent hydrogen atoms). Additionally, it was anticipated for one of the 
integrated peaks to sum to 1 in representation of Letter e, which only possesses 1 hydrogen atom.    
The spectrum matched the expected results. Each distinct hydrogen atom, or set of 
equivalent hydrogen atoms, was represented by a distinct peak within the spectrum as hoped. 
Letters a, b, c, and d each possessed 2 equivalent hydrogen atoms and integrated to 1.94, 2.00, 
2.22, and 2.03 respectively. Letter e possessed 1 hydrogen atom and integrated to 0.92. Letter b’s 
peak was shifted most upfield in comparison to the rest of the peaks because of its isolation from 
all electron-withdrawing groups present within Compound 6.  
Figure 9 – 13C-NMR for Compound 6 
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 It was initially expected that the carbon atoms represented by letters c and d would both 
have been shifted further downfield. Based on the 13C-NMR, it is very likely that there are 
impurities present within the desired final compound.  
Figure 10 – Mass Spectrometry for Compound 6 
 
 Mass spectrometry will produce fragments of an initial molecule that possess differing 
molecular weights relative to the portions of the initial molecule that still remain. In the case of 
Compound 6, it was not entirely certain whether the final compound would possess a cyclic or 
acyclic structure initially. If Compound 6 were cyclic, it would be expected for its molecular 
weight prior to fragmentation to be near its exact mass of 146.081 m/z. If Compound 6 were 
acyclic, it would be expected for its molecular ion before fragmentation to be near its exact mass 
of 226.007 m/z. Mass spectrometry results strongly suggests Compound 6 is acyclic, as its 
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molecular ion’s weight is equal to 226.00277 m/z and has a percent error of 0.0000187 % (18.7 
ppm). In further support of that claim, TLC results obtained as detailed in the Experimental 
Procedure provided further evidence of the formation of the acyclic final product. Ninhydrin will 
only show positive spotting for primary and secondary amines but will not show spotting for any 
tertiary amines. If Compound 6 were cyclic, and subsequently possessed a tertiary amine within 
its structure, ninhydrin would not be expected to produce any positive spots. But ninhydrin was 
found to produce positive spotting for Compound 6, strongly suggesting that Compound 6 is 
acyclic and not cyclic. 
 To determine if the synthesis of Compound 7 was successful, mass spectrometry and 1H-
NMR were analyzed. The results are shown in Figures 11 and 12, respectively.  
Figure 11 – Mass Spectrometry for Compound 7 
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 Compound 7’s molecular weight after the loss of two nitrogen atoms is exactly 160.084 
m/z. The mass spectrometry results obtained for the same molecular fragment of Compound 7 
portrayed a molecular weight of 160.09521 m/z. The percent error associated with the molecular 
fragment’s weight determination was 0.000070 % (70.0 ppm). Although this cannot entirely 
confirm the presence of Compound 7, it strongly suggests that the synthesis occurred as hoped.    
Figure 12 – 1H-NMR for Compound 7 
 
 The 1H-NMR spectrum obtained suggests the successful formation of Compound 7. The 
peaks representing the hydrogen atoms located on Letters a, b, c, and d each had an integration of 
approximately 2 as expected. Letter e, which represents a single hydrogen atom, integrated as 
expected to 1.13 (approximately 1). Additionally, Letter b, which is shifted further upfield 
because of its isolation from electron withdrawing groups, correctly is portrayed by a multiplet in 
a
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the NMR spectrum, suggesting that its neighboring carbon atoms possess multiple hydrogen 
atoms (the neighboring carbon atoms possess a combined 4 hydrogen atoms). Letter a, which is 
slightly further downfield than Letter b, is correctly portrayed as a triplet in the NMR spectrum, 
as its neighboring carbon atom possesses 2 hydrogen atoms.  
 Furthermore, the peaks shifted further downfield represented Letters d and e, the two sets 
of hydrogen atoms nearest the hydroxyl group and carboxylic acid group respectively as 
anticipated.  
 To analyze the potential formation of Compound 8, 1H-NMR, 13C-NMR, and mass 
spectrometry data were analyzed. The results are portrayed in Figures 13, 14, and 15 respectively. 
Figure 13 – 1H-NMR for Compound 8 
 
a
b
c
d
ab
c
d
 29 
 It was initially expected for the 1H-NMR spectrum of Compound 8 to possess four 
distinct peaks that collectively summed to an integration value of approximately 6. The spectrum 
matched the expected results. The significant promising piece of the spectrum was the singlet 
peak located at 2.66 ppm with an integration of 1.00. This peak corresponded to the alkyne 
hydrogen atom and strongly suggests the correct synthesis of the final compound. In addition, the 
hydrogen atoms represented by Letters a and d integrated to 1.000 and 1.317 respectively while 
the hydrogen atoms corresponding to Letters b and c integrated to 1.869 and 1.759 respectively. 
It was expected for Letters a and d to have integration values equal to approximately 1 and 
Letters b and c to have integration values equal to approximately 2; the spectrum very closely 
portrayed the expected integration values. 
Figure 14 – 13C-NMR for Compound 8 
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 The 13C-NMR data portrayed the expected peak locations for each of the 6 carbon atoms 
present within Compound 8. Based on this spectrum, it can be inferred that Compound 8 was 
synthesized as hoped. 
Figure 15 – Mass Spectrometry for Compound 8 
 
 The molecular ion of Compound 8 has an exact weight of 146.081 m/z. Mass 
spectrometry results shown in Figure 14 portray the molecular ion having a weight of 146.08989 
m/z, which represents a percent error value of 0.0000609 % (60.9 ppm) from the exact weight of 
the molecular ion. Although mass spectrometry cannot confirm the successful formation of 
Compound 8, it is strongly suggestive of the correct synthesis of Compound 8.  
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Conclusion 
 Based on the data collected from 1H-NMR, 13C-NMR, and mass spectrometry, it is 
suggested that the syntheses of (S)-3-azido-N-(1-carboxy-2-hydroxyethyl)propan-1-aminium (7) 
and (S)-N-(1-carboxy-2-hydroxyethyl)prop-2-yn-1-aminium (8) were successful. While it cannot 
be entirely confirmed, mass spectrometry and NMR data collected do provide strong evidence of 
the correct syntheses of 7 and 8. The NMR data collected for the synthesis of Compound 6, 
however, suggests that the final compound likely has more impurities than hoped. Compounds 7 
and 8 have already provided very strong results in initial testing of competitive inhibition against 
the phosphatidylserine synthase Cho1 within C. albicans as illustrated in Figures 1 and 2. 
Compound 6 will soon be tested to determine its degree of competitive inhibition of Cho1 in C. 
albicans as well. In future months, further testing of Compounds 6, 7, and 8, along with new 
serine analogs that have not yet been synthesized, will hopefully confirm their degree of 
competitive inhibition of Cho1 within C. albicans. The hope is that the syntheses of these 
compounds will in turn lead to successful inhibition of C. albicans, the design of a 
pharmaceutical drug that can serve as an antifungal therapeutic, and the ultimate diminishing of 
the harmful effects of Fungal Endocarditis.  
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